These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25566896)

  • 1. Drug eruptions induced by allopurinol associated with HLA-B*5801.
    Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
    Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.
    Wu R; Cheng YJ; Zhu LL; Yu L; Zhao XK; Jia M; Wen CH; Long XZ; Tang T; He AJ; Zeng YY; Ma ZF; Zheng Z; Ni MZ; Cai GJ
    Oncotarget; 2016 Dec; 7(49):81870-81879. PubMed ID: 27835909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
    Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
    BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
    Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
    Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
    Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.
    Yun J; Mattsson J; Schnyder K; Fontana S; Largiadèr CR; Pichler WJ; Yerly D
    Clin Exp Allergy; 2013 Nov; 43(11):1246-55. PubMed ID: 24152157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
    Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
    J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
    Caldarola G; Sollena P; Peris K; De Simone C
    J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
    [No Abstract]   [Full Text] [Related]  

  • 10. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
    Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics begins to deliver on its promises.
    Li-Wan-Po A
    BMJ; 2015 Sep; 351():h5042. PubMed ID: 26400246
    [No Abstract]   [Full Text] [Related]  

  • 12. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions.
    Park HJ; Yun J; Kang DY; Park JW; Koh YI; Kim S; Kim SH; Nam YH; Jeong YY; Kim CW; Park HK; Kim SH; Kang HR; Jung JW;
    J Allergy Clin Immunol Pract; 2019; 7(8):2739-2749.e3. PubMed ID: 31201937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.
    Cao ZH; Wei ZY; Zhu QY; Zhang JY; Yang L; Qin SY; Shao LY; Zhang YT; Xuan JK; Li QL; Xu JH; Xu F; Ma L; Huang HY; Xing QH; Luo XQ
    Pharmacogenomics; 2012 Jul; 13(10):1193-201. PubMed ID: 22909208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of HLA-B*58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification.
    Kwok J; Kwong KM
    Br J Dermatol; 2013 Mar; 168(3):526-32. PubMed ID: 23066948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans.
    Yang F; Yang Y; Zhu Q; Chen SA; Fu X; Yan S; Meng C; Ma L; Sun X; Xu J; Luo X; Xing Q
    J Investig Dermatol Symp Proc; 2015 Jul; 17(1):29-31. PubMed ID: 26067314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
    Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
    Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities.
    Fathallah N; Ben Salem C; Slim R; Kaabia N; Letaief A; Bouraoui K
    J Clin Rheumatol; 2010 Jun; 16(4):170-1. PubMed ID: 20511977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.